Skip Header
Important information: The value of investments can go down as well as up so you may get back less than you invest. Investors should note that the views expressed may no longer be current and may have already been acted upon. This is a third-party news feed and may not reflect Fidelity’s views.

Canaccord Genuity hikes target price for MP Evans

(Sharecast News) - Canaccord Genuity has hiked its target price for palm oil group MP Evans after the AIM-listed firm's positive first-half results on Monday, saying the stock continues to be "undervalued". The Indonesia-focused palm oil producer said that, while output fell slightly on last year, turnover for the six months to 30 June was $179.4m, up from $163.7m a year earlier.

Gross profits totalled $63.4m, up 51% on last year, helped by a 13% increase in crude palm oil (CPO) prices and an increase in the gross margin to 35% from 26%. Margins supported by a change in input mix with more of the company's own harvest being processed this year, bolstered by lower fertiliser costs due to the timing of application, and a weakening Indonesia currency.

"Following July's indication of a good H1-25, MP Evans has now confirmed it. Operational delivery was solid, with the crop mix shifting further toward owned fruit and scheme smallholders, and away from independent purchases," Canaccord Genuity said in a research note.

"Deliberate restraint on third-party buying reduced external crop purchases by 39% to just under 120k tonnes, which took total processed volumes down 3% to 737.7k tonnes, but preserved quality and margins," the broker explained.

Canaccord Genuity kept a 'buy' rating on the stock and lifted its target price for the shares from 1,500p to 1,650p.

Trading at an enterprise value-to-EBITDA ratio of just 5x on 2026 estimates, the stock "remain[s] attractive relative to its Asian peers", the broker said.

Shares were down 1.1% at 1,315p by 1139 BST, having risen more than 5% over the preceding two sessions.

Share this article

Related Sharecast Articles

GSK gets preliminary nod for two respiratory drugs in Europe
(Sharecast News) - GSK said on Friday afternoon that two of its respiratory medicines had received positive opinions from the European Medicines Agency's Committee for Medicinal Products for Human Use, bringing the company closer to potential approvals across severe asthma, chronic rhinosinusitis with nasal polyps and chronic obstructive pulmonary disease.
Shore Capital hails improved US biotech funding environment for hVIVO
(Sharecast News) - Shares in AIM-listed hVIVO were continuing their recent surge on the back of encouraging signs from the US biotech market, which broker Shore Capital said has created a "much more favourable environment" for the company.
Weir to buy remaining 50% stake in Chile JV ESEL for £56m
(Sharecast News) - Weir said on Friday that it has agreed to buy the remaining 50% share of its Chile-based joint venture ESEL for a sterling equivalent purchase price of £56m.
Jefferies downgrades Whitbread, upgrades IHG
(Sharecast News) - Jefferies downgraded Whitbread to 'hold' from 'buy' on Friday as it applied the reverse upgrade to InterContinental Hotels.

Important information: This information is not a personal recommendation for any particular investment. If you are unsure about the suitability of an investment you should speak to one of Fidelity’s advisers or an authorised financial adviser of your choice. When you are thinking about investing in shares, it’s generally a good idea to consider holding them alongside other investments in a diversified portfolio of assets. Past performance is not a reliable indicator of future returns.

Award-winning online share dealing

Search, compare and select from thousands of shares.

Expert insights into investing your money

Our team of experts explore the world of share dealing.